Implementation of adaptive methods in early-phase clinical trials

Recent developments in the implementation of novel designs for early-phase combination studies

(2015) N. A. Wages et al.   ANNALS OF ONCOLOGY

Statistical controversies in clinical research: requiem for the 3 + 3 design for phase I trials

(2015) X. Paoletti et al.   ANNALS OF ONCOLOGY

A Phase I/II adaptive design to determine the optimal treatment regimen from a set of combination immunotherapies in high-risk melanoma

(2015) Nolan A. Wages et al.   Contemporary Clinical Trials

Scientific Review of Phase I Protocols With Novel Dose-Escalation Designs: How Much Information Is Needed?

(2015) Alexia Iasonos et al.   JOURNAL OF CLINICAL ONCOLOGY

A Phase I/II adaptive design for heterogeneous groups with application to a stereotactic body radiation therapy trial

(2015) Nolan A. Wages et al.   PHARMACEUTICAL STATISTICS

bcrm: Bayesian Continual Reassessment Method Designs for Phase I Dose-Finding Trials

(2015) Michael Sweeting et al.   Journal of Statistical Software

Three steps to writing adaptive study protocols in the early phase clinical development of new medicines

(2014) Ulrike Lorch et al.   BMC Medical Research Methodology

Adaptive designs for identifying optimal biological dose for molecularly targeted agents

(2014) Yong Zang et al.   Clinical Trials

Adaptive Dose-Finding Studies: A Review of Model-Guided Phase I Clinical Trials

(2014) Alexia Iasonos et al.   JOURNAL OF CLINICAL ONCOLOGY

Bayesian optimal interval designs for phase I clinical trials

(2014) Suyu Liu et al.   JOURNAL OF THE ROYAL STATISTICAL SOCIETY SERIES C-APPLIED STATISTICS

Principles of dose finding studies in cancer: a comparison of trial designs

(2013) Thomas Jaki et al.   CANCER CHEMOTHERAPY AND PHARMACOLOGY

Sample size formulae for the Bayesian continual reassessment method

(2013) Ying Kuen Cheung   Clinical Trials

Performance of two-stage continual reassessment method relative to an optimal benchmark

(2013) Nolan A Wages et al.   Clinical Trials

pocrm: An R-package for Phase I trials of combinations of agents

(2013) Nolan A. Wages et al.   COMPUTER METHODS AND PROGRAMS IN BIOMEDICINE

Modified Toxicity Probability Interval Design: A Safer and More Reliable Method Than the 3 + 3 Design for Practical Phase I Trials

(2013) Yuan Ji et al.   JOURNAL OF CLINICAL ONCOLOGY

Dose-Finding Trial Designs for Combination Therapies in Oncology

(2013) Sumithra J. Mandrekar   JOURNAL OF CLINICAL ONCOLOGY

Phase I Study of Neratinib in Combination With Temsirolimus in Patients With Human Epidermal Growth Factor Receptor 2–Dependent and Other Solid Tumors

(2013) Leena Gandhi et al.   JOURNAL OF CLINICAL ONCOLOGY

Phase I Trial of Induction Histone Deacetylase and Proteasome Inhibition Followed by Surgery in Non–Small-Cell Lung Cancer

(2012) David R. Jones et al.   Journal of Thoracic Oncology

Extended model-based designs for more complex dose-finding studies

(2011) John O'Quigley et al.   STATISTICS IN MEDICINE

Maintenance therapy with low-dose azacitidine after allogeneic hematopoietic stem cell transplantation for recurrent acute myelogenous leukemia or myelodysplastic syndrome

(2010) Marcos de Lima et al.   CANCER

Continual Reassessment and Related Dose-Finding Designs

(2010) John O’Quigley et al.   STATISTICAL SCIENCE

Dose Escalation Methods in Phase I Cancer Clinical Trials

(2009) Christophe Le Tourneau et al.   JNCI-Journal of the National Cancer Institute

A comprehensive comparison of the continual reassessment method to the standard 3 + 3 dose escalation scheme in Phase I dose-finding studies

(2008) Alexia Iasonos et al.   Clinical Trials